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by C-terminal Src kinase (Csk), and the level of c-Src is also regulated via the ubiquitin-proteasome pathway, which is mediated by E3 ubiquitin-ligase Cbl and Cullin-5 (Hakak & Martin, 1999; Laszlo & Cooper, 2009; Okada, Nada, Yamanashi, Yamamoto, & Nakagawa, 1991) . Moreover, the function of c-Src is regulated by cellular localization which defines the transducing oncogenic signaling (Oneyama et al., 2008a) . Thus, the oncogenic potential of c-Src is suppressed even when c-Src is abundantly expressed, and the c-src gene is rarely mutated in human cancers (Irby & Yeatman, 2000) . Thus, the disruption of c-Src regulatory mechanisms may trigger cancer phenotypes such as uncontrolled proliferation, enhanced survival, and invasiveness, in cooperation with other oncogenic signals (Ishizawar & Parsons, 2004) . Once activated, such as by growth factors or integrins, c-Src triggers downstream signaling pathways, including the Ras/MAPK, phosphatidylinositol 3-kinase (PI3K)/AKT, and STAT pathways, and results in malignant phenotypic changes (Ingley, 2008) . A large body of evidence has showed the importance of c-Src in cancer progression, but the molecular mechanisms responsible for the upregulation of c-Src in some cancers are not well understood (Frame, 2002; Ishizawar & Parsons, 2004; Yeatman, 2004) . In recent years, the dysregulation of microRNAs (miRNAs) that negatively regulate c-Src mRNA has been showed in a subset of cancers.
miRNAs are endogenous and evolutionarily conserved noncoding RNAs of approximately 22 nucleotides that bind to complementary sequences within target mRNA, thereby either inhibiting translation or causing mRNAs to become degraded (Ha & Kim, 2014) . miRNAs control diverse cellular functions and fine-tune various signaling pathways (Mukherji et al., 2011) . They also diversely regulate gene expression; a single miRNA can target multiple target genes or a single gene can be targeted by multiple miRNAs (Guo, Ingolia, Weissman, & Bartel, 2010) . As miRNAs potentially act as key regulators of complex signaling networks, abnormal miRNA expression patterns found in human cancers result in the altered expression of oncogenes or tumor suppressor genes (Di Leva & Croce, 2013; Kunej, Godnic, Horvat, Zorc, & Calin, 2012; Zhang, Pan, Cobb, & Anderson, 2007) .
To verify the role of c-Src in cancer progression, we developed a model system using Csk-deficient fibroblasts (Csk −/− cells) that can be transformed by c-Src (Oneyama, Hikita, Nada, & Okada, 2008b) . A series of studies have shown that this system could be useful in the identification of critical pathways leading to c-Src-induced transformation. Then, we investigated the mechanisms underlying c-Srcmediated tumor progression, focusing on the contribution of miRNAs. Furthermore, expression profiling of miRNAs in this model system revealed that a specific set of miRNAs are differentially regulated by c-Src (Oneyama et al., 2011) . Because many miRNAs are down-regulated in human cancers by methylation, the loss of heterogeneity, or for other reasons, we focused on down-regulated miRNAs in c-Src transformation (Calin & Croce, 2006) . By studying the function of these miRNAs, we uncovered miRNA-mediated c-Src oncogenic signaling and cross talk between c-Src and other oncogenic signaling pathways, such as the mammalian target of rapamycin (mTOR) pathway; miR-99a/mTOR and miR-424/503-Rictor; and focal adhesion-mediated pathways, such as miR-542-3p/ILK and miR-27b/paxillin (Matsuyama, Okuzaki, Okada, & Oneyama, 2016; Oneyama et al., 2011 Oneyama et al., , 2012 Oneyama et al., , 2013 . These miRNAs are involved in tumor growth and cancer progression through perturbed expression of their target genes (Oneyama & Okada, 2015) . In this study, to verify the upregulation of c-Src in human cancers, we investigated miRNAs with complementarity to the 3′-UTR of c-Src mRNA. We examined colon cancer cells that harbor c-Src upregulation and focused our analysis on miR-137 based on its significant down-regulation in colon cancer cells/tissues. Functional analysis of miR-137 showed that miR-137 functions as a suppressor of tumor growth and cell adhesion and invasiveness as well as of the downregulation of c-Src in colon cancer cells. We also showed that miR-137 directly targets not only c-Src but also AKT2 and paxillin to suppress tumor growth and invasiveness, respectively. Because AKT2 is a downstream effector of Src and paxillin serves as a platform for adaptor proteins that induce focal adhesion-mediated Src activation, these targets of miR-137 synergistically evoke c-Src oncogenic signaling and result in the promotion of cancer phenotypes, such as tumorigenesis, invasion, and metastasis. Moreover, we showed that miR-137-mediated down-regulation of c-Src signaling suppressed results to change the expression of Src-related miRNAs such as miR-99a, miR-27b, miR-503, and miR-542-3p. These findings suggest that miR-137 functions as a key miRNA, controlling Src-mediated tumor progression. Furthermore, miR-137 is down-regulated during the acquisition of cellular immortalization before oncogene-induced transformation, which is common in both human and mouse cells. Our results raise the possibility that repression of miR-137 accompanied by immortalization induces c-Src signaling and promotes the growth and invasive potential of various human cancers.
| RESULTS

| Down-regulation of miR-137 in human colon cancers that harbor c-Src upregulation
To examine whether c-Src is regulated by miRNA in human cancers, we carried out a bioinformatic search (TargetScan and PicTar) and examined the expression levels of miRNA candidates with complementarity to the 3′-UTR of c-Src mRNA in several human colon cancer cell lines that overexpress c-Src (Figure 1a) . The qRT-PCR analysis of the | Genes to Cells
candidate miRNAs showed that the expression of miR-137 was much lower in most colon cancer cells than in normal cells ( Figure 1b) . Next, we verified the expression levels of miR-137 in 10 pairs of colon tumors and adjacent noncancerous tissues using qRT-PCR. miR-137 was significantly down-regulated in nine of the ten tumor samples examined ( Figure 1c) . Moreover, Western blot analysis of the tissue samples showed that Src expression was higher in tumors than in noncancerous tissues, which mostly exhibited miR-137 down-regulation (Figure 1d ). These observations suggest that there is an inverse correlation between the expression of miR-137 and Src in colon cancer tissues as well as colon cancer cells (Figure 1a-d ).
| Src is a target of miR-137
To verify the relationship between Src and miR-137, we validated our findings using the luciferase reporter assay in HCT116 cells. This assay showed that the introduction of miR-137 significantly suppressed the expression of the Src reporter by specifically targeting the predicted miR-137 binding sequences in the 3′ untranslated region of the Src mRNA (Figure 2a,b) . Conversely, the inactivation of miR-137 by anti-miR-137 enhanced the expression of the Src reporter in HCT116 cells in which miR-137 is still expressed, albeit at a low level (Figures 1b and 2c) . Western blot analysis showed that the Src protein was significantly down-regulated by the expression of miR-137 in HT29 and HCT116 cells (Figure 2d ). In contrast, the introduction of anti-miR-137 increased Src expression in these cells (Figure 2d ). These findings suggest that Src is directly targeted by miR-137.
We then examined the impact of miR-137 expression on the responsiveness of HCT116 cells to dasatinib, a specific Src kinase inhibitor. The growth assay for HCT116 cells in the absence and/or presence of dasatinib showed that dasatinib suppressed Src activity and cell growth in a dose-dependent manner and that the introduction of miR-137 significantly sensitized these cells to the suppressive effect of dasatinib (Figure 2e ). These findings show that miR-137 directly targets Src, and that down-regulation of miR-137 is associated with the upregulation of Src signaling in colon cancer cells.
| miR-137 regulates tumor growth of colon cancer cells
To elucidate the role of Src in the tumor growth of colon cancer cells, we used shRNAs to knockdown Src in HT29 and HCT116 cells (Figure 3a) . Soft agar colony formation was suppressed by knockdown of Src to a level comparable with that in miR-137-transfected cells (Figures 2d and 3a) . Restoration of Src expression using the mouse gene, which is resistant to sh-RNA-mediated degradation, fully rescued the colony-forming activity (Figure 3b ). Using these colon cancer cells, we examined the role of miR-137 in HT29 and HCT116 cells. The expression of miR-137 suppressed the colony-forming activity of these cells (Figure 3c ). The growth suppressive effect of miR-137 was more evident in vivo: Tumorigenesis of these cells in nude mice was potently suppressed by miR-137 expression (Figure 3d ). Collectively, these findings suggest that miR-137 plays a crucial role in regulating tumor growth.
| miR-137 suppresses tumor growth by targeting Src and AKT2
We next examined whether the tumor-suppressive effect of miR-137 is mediated by Src down-regulation. When Src open reading frame (ORF) cDNA, which is resistant to miR-137, was introduced into miR-137-treated HCT116 cells, the colony-forming activity was only moderately rescued (Figure 4a,b) . These results suggest that Src contributes to promoting tumor growth of colon cancer cells, but the growth suppressive effect of miR-137 is not solely attributed to Src down-regulation. Thus, we further searched for other targets via a bioinformatic search (TargetScan). Based on previous studies, AKT2 was identified among the candidates as a target likely to be involved in tumor growth (Dillon & Muller, 2010) . Western blot analysis showed that AKT2 protein was down-regulated by the introduction of miR-137 to HCT116 cells ( Figure 4a) ; thus, we questioned whether AKT2 might be regulated by miR-137. The luciferase reporter activities of constructs containing the predicted target sites of AKT2 were significantly reduced in miR-137-transfected HCT116 cells (Figure 4c,d ). The rescue experiments using ORFs of AKT2 and Src cDNAs showed that restoration of both AKT2 and Src was sufficient to significantly recover the To further verify the importance of the down-regulation of miR-137 on the acquisition of tumorigenesis, we examined the effect of inactivating miR-137 using anti-miR-137 in nontransformed human keratinocyte HaCaT cells. When introduction of anti-miR-137 into HaCaT cells, Src and AKT2 were upregulated following the introduction of antimiR-137 into HaCaT cells, and anchorage-independent growth was observed in these cells (Figure 4e ,f). These results suggest that upregulation of Src and AKT2 by the down-regulation of miR-137 can control the potential for tumor growth within a range that could be regulated by miR-137. However, the colony-forming activity of antimiR-137-treated HaCaT cells was significantly weaker than that of cancer cells (Figures 3c and 4f ). This indicates that increased expression of Src and AKT2 is required but is insufficient for inducing full transformation, because the functional activities are stringently regulated, and other critical pathways, such as the MAPK pathway, which are required for cell growth, were not activated by the expression of Src and AKT2. Nevertheless, miR-137-mediated Src/AKT upregulation contributes to the acquisition of tumor growth. 
| miR-137 suppresses cell adhesion and invasion of colon cancer
As Src is involved in cancer malignancies (Summy & Gallick, 2003) , we examined the effects of the miR-137-Src pathway on the cell morphology, cell adhesion, and invasiveness of HCT116 cells. The introduction of miR-137 to HCT116 cells induced striking morphological changes, leading to a spindle-like shape, and similar effects of miR-137 on the cell morphology were also observed in other colon cancer cells such as HT29 cells (Figure 5a and data not shown). Notably, staining for F-actin and vinculin (focal contact marker) revealed that miR-137-treated HCT116 cells exhibited disrupted stress fibers and suppressed the formation of focal adhesion ( Figure 5c , upper panels). We next examined whether miR-137-mediated Src down-regulation caused these changes in cytoskeletal organization and the formation of focal contacts. However, when Src ORF cDNA was introduced into miR-137-treated HCT116 cells, neither the disruption of stress fibers nor the reduced number of focal contacts was rescued (Figure 5a,c) . We searched potential targets related to the focal adhesion of miR-137 in human genes using TargetScan, referred with reports that miR-137 targets paxillin and regulates invasiveness (Bi, Han, Bi, Gao, & Wang, 2014; Chen et al., 2013) . Overexpression of paxillin in miR-137-treated cells did not reverse the morphological changes, but that of Src and paxillin was able to nearly completely rescue these changes (Figure 5a,c) . Furthermore, because focal adhesions are crucial for cell adhesion, motility, and the invasion of cancer cells, we tested whether the miR-137-Src/paxillin pathway could control adhesion and invasion in these cells. Consistent with the changes in cell morphology, the adhesion of HCT116 cells to fibronectincoated dishes was remarkably suppressed by the expression of miR-137; however, introduction of the Src and paxillin ORF into miR-137-treated HCT116 cells successfully restored cell adhesion (Figure 5d ). Furthermore, we assessed the in vitro invasive potential of miR-137-treated HCT116 cells in a Matrigel-based assay. Likewise, the introduction of miR-137 potently suppressed the invasiveness of these cells, and expression of the Src and paxillin ORFs into miR-137-treated HCT116 cells restored the invasive activity of these cells (Figure 5e ). These findings suggest that both Src and paxillin are targets of miR-137 responsible for controlling cell adhesion and the invasiveness of colon cancer cells.
| miR-137 is down-regulated in the early phase of cancer progression
Src is frequently overexpressed and activated in a wide variety of human cancers, suggesting the importance of Src in cancer progression (Ishizawar & Parsons, 2004; Yeatman, 2004) . To follow the phase of cancer progression leading to the downregulation of miR-137, we next examined the expression of miR-137 in the phase of immortalization and transformation using established model systems of cancer, human mammary gland epithelial cells (HMECs) (Elenbaas et al., 2001) , and murine embryonic fibroblasts (MEFs). When HMECs were introduced by SV40 large T (LT) and hTERT and acquired the immortalized phenotype (HMLEs), the expression of miR-137 was significantly down-regulated ( Figure 6a , left panel). Consequently, miR-137 was also down-regulated in HMLEs that were transformed by oncogenes such as HrasV12 ( Figure 6a , left panel). The expression of Src was 
| The effect of miR-137 on Src-related oncogenic pathways
Finally, we verified the effect of miR-137 on the expression of miRNAs related to Src activation. As mentioned above, the introduction of miR-137 suppressed the tumor growth of HT29 cells that harbor Src upregulation and are sensitive to Src inhibitors (Figures 2d,e, and 3c). In HT29 cells introduced to miR-137, miR-137 expression suppressed Src expression and consequent Src activation, tyrosine phosphorylation of cellular proteins, and the activation of ERK or AKT downstream of Src (Figure 6c ). Previously, we showed the down-regulation of miRNAs in Src activation in a model system based on Csk −/− cells (Oneyama & Okada, 2015) . To examine whether the miR-137-Src axis is indeed functional in human cancers, we analyzed miRNAs, including miR-27b, miR-99a, miR-503, and miR-542 in miR-137-treated HT29 cells using qRT-PCR. The expression of these miRNAs in HT29 cells was increased by the introduction of miR-137 and was accompanied by the inactivation of Src signaling (Figure 6c,d) . Overall, our findings suggest that down-regulation of miR-137 is induced in the early stage of human cancers and is tightly associated with the promotion of tumor growth via the upregulation of Src/AKT2 and tumor progression by means of upregulation of the Src/paxillin pathways (Figure 7 ).
| DISCUSSION
In this study, we identified miR-137 as a regulator of Src upregulation in the progression of human colon cancers and also showed that miR-137 plays a tumor-suppressive role in human colon cancers. miR-137 suppressed both the cancer phenotypes of tumorigenesis and tumor progression involved in the function of Src. miR-137 directly targets Src/AKT2, which are required for tumor growth, and in contrast, Src/ paxillin, which are required for tumor progression such as the formation of focal adhesion, cell adhesion, and invasion of cancer cells, respectively. The down-regulation of miR-137 is induced in the early phase of cancer progression, which results in the upregulation of c-Src, AKT, and paxillin, which in turn activates c-Src-related oncogenic signaling, leading to the promotion of tumor growth and invasion (Figure 7) .
Multiple studies have shown upregulation of c-Src in a broad range of cancer types, including colon, breast, prostate, pancreas, lung, and head and neck carcinoma, as well as glioma and melanoma. In particular, the Src pathway is activated in 80% of all human colon tumors, and it has been suggested that Src activation has a central role in the induction and progression of tumors (Chen, Elfiky, Han, Chen, & Saif, 2014) . Src activity is elevated in adenomatous polyps and is the highest in liver metastatic lesions (Cartwright, Meisler, & Eckhart, 1990) .
c-Src is regulated in terms of both protein (mRNA) levels and the levels of activity by a range of mechanisms. The levels of c-Src protein are negatively regulated by the E3 ubiquitin-ligase Cbl or Cullin-5, which leads to c-Src ubiquitylation and subsequent degradation by the proteasome (Hakak & Martin, 1999; Laszlo & Cooper, 2009 ). The cysteine residues of Src are important for its stability and promote Src-induced transformation (Senga et al., 2000) . At the point of the levels of the c-src gene, it has been shown that there is heterogeneity in the Src gene copy number, with most of the CRC cell lines and explants having a gain in the Src gene number; further, an increase in the Src gene copy number is associated with resistance to the Src inhibitor saracatinib (Arcaroli et al., 2010) . Moreover, recent studies have showed that the expression of Src can be disrupted via several miRNAs in some human cancers (Oneyama & Okada, 2015) .
F I G U R E 7
A schematic model of the function of miR-137. The down-regulation of miR-137 in the early phase of cancer progression results in the upregulation of c-Src, AKT2, and paxillin, which in turn down-regulates c-Src-related tumor suppressor miRNAs and accelerates the promotion of tumor growth and invasion miR-23b is reportedly silenced by methylation in prostate cancers, and re-expression of miR-23b has been shown to reduce Src protein levels (Majid et al., 2012) . Furthermore, the same gene cluster, miR-23b~27b~24-1, is repressed by c-Src-induced transformation, suggesting that upregulation of c-Src expression and activity amplifies the positive feedback loop mediated by the miR-23b~27b~24-1 gene cluster and promotes the tumor malignancy mediated by c-Src (Matsuyama et al., 2016) . miR-205 has also been shown to be down-regulated and to target Src family kinases, including c-Src, Yes, and Lyn, in renal cell carcinoma; miR-205 can also suppress cell proliferation, migration, and invasion in renal cancer cells (Yonezawa et al., 2005) . Furthermore, overexpression of miR-31 down-regulated in melanoma tumors suppressed the migration and invasion of melanoma cells by targeting several targets, including c-Src (Asangani et al., 2012) . The expression of miR-31 was also suppressed by its targets, by enhancing activity of EZH2-mediated histone methylation. Furthermore, miR-203 directly suppresses Src expression and consequently triggers the suppression of downstream pathways, such as the Ras/ERK pathway in lung cancer cells. An inverse correlation has been shown between miR-203 and Src protein levels in lung cancer tissues, and miR-203 mainly targets Src to exert its tumor-suppressive function during lung cancer progression (Rothschild, Gautschi, Haura, & Johnson, 2010) . These lines of evidence highlight a critical role of miRNA-mediated regulation of Src in the control of tumor progression in various human cancers.
The substantial down-regulation of miR-137 in human colon cancers suggests a crucial role for miR-137 as a regulator of these cancers. The miR-137 gene is located on chromosome 1p22 within the noncoding RNA gene, is embedded in a CpG island, and is frequently silenced by methylation in several tumors (Balaguer et al., 2010) . Down-regulation of miR-137 has been found in many cancers, including colon, breast, gastric cancer, head and neck carcinoma, and melanoma, by inhibiting cell proliferation, metastasis, and invasion (Shen et al., 2016; Smith et al., 2015) . qRT-PCR analysis of the miR-137 expression levels in a panel of colon cancer cells/tissues revealed a substantial reduction in miR-137 expression to less than one tenth that of the expression observed in normal colon cells/tissues (Figure 1) , which suggests that miR-137 may be down-regulated by epigenetic silencing in these colon cancer cells. Furthermore, our study shows that the expression of miR-137 can be down-regulated in the phase of acquisition of immortalization in human cells as well as in mouse cells (Figure 6a) . However, the downstream mechanisms that lead to changes in miR-137 gene expression in cell immortalization remain unclear. Additional extensive analysis is necessary to elucidate the precise mechanism of miR-137 down-regulation. Hence, this observation suggests that downregulation of miR-137 contributes to the upregulation of c-Src before the acquisition of oncogene-induced transformed phenotypes (Figure 6b) .
We also observed that ectopic expression of miR-137 suppressed anchorage-independent growth and tumorigenesis via the down-regulation of c-Src and AKT2. AKT2 is a major downstream effector of PI3K, and this pathway is frequently dysregulated in several cancers and promotes tumor growth, survival, metabolism, and migration. There is increasing evidence that the AKT family, including AKT1, AKT2, and AKT3, has unique roles in cancer phenotypes and that AKT2 promotes the metastasis of tumor cells, in contrast to AKT1, which plays an important role in breast cancer induction (Dillon & Muller, 2010) ; however, the contribution of AKT2 to the progression of cancers has not been fully addressed. In this study, we found that miR-137-mediated suppression of tumor growth in colon cancer cells is completely restored by the re-expression of c-Src and AKT2 (Figure 4b ). Despite the differences observed in the role of AKT2, this is the first evidence suggesting the importance of the miR-137-Src/AKT2 axis in tumor growth.
In addition to its suppressive effect on tumor growth, the expression of miR-137 induced disruption of focal adhesions, which are important for cancer invasion and metastasis (Figure 5c ). The re-expression of c-Src and paxillin in miR-137-treated cancer cells completely rescued cell adhesion and invasion ability although c-Src alone had insufficient effects on these cancer phenotypes. Paxillin is upregulated in a wide variety of human cancers and is involved in integrin-mediated cancer malignancies (Azuma et al., 2005; Shi et al., 2010) . Once integrin-mediated signaling is activated by cell-ECM adhesion, paxillin is phosphorylated by c-Src and FAK and acts as a platform for adaptor proteins, leading to downstream intracellular signaling (Burridge, Turner, & Romer, 1992; Schaller, 2001) . In contrast, our previous research showed that paxillin expression is controlled by miR-27b, which is down-regulated by Src activation (Matsuyama et al., 2016) . In this study, we showed that miR-137-mediated upregulation of paxillin/c-Src expression induces Src-mediated oncogenic signals evoked from focal adhesions, which suppress the expression of miR-27b and result in the acceleration of Src-mediated malignant phenotypes such as invasion and metastasis. Concurrently, Src activation suppresses miR-542-3p expression, and miR-542-3p-mediated ILK upregulation promotes the positive feedback loop of Src activation initiated by extracellular signals such as integrin and growth factors (Oneyama et al., 2012) . These lines of evidence suggest that miR-137-mediated upregulation of c-Src/paxillin signaling results in Src oncogenic signaling evoked from focal adhesions via Src-related miRNAs and elicit malignant phenotypes of tumors. Because miRNA can generally target multiple genes simultaneously, our results cannot exclude that miR-137 targets other genes in human cancer cells. A comprehensive analysis such as the RNA-seq might contribute to gain more insight into miR-137-mediated cancer progression.
In this study, we have shown a crucial role of miR-137-Src/AKT2/paxillin in controlling the Src-mediated tumor progression of a wide array of human cancers. Given that Src upregulation is frequently observed in some types of human cancers, miR-137-mediated regulation of Src signaling could represent a leap forward in our understanding of cancer aetiology. Our study provides insights into the function of this new signaling axis, and miR-137 could serve as a potential target for therapeutic intervention in a range of human cancers.
| EXPERIMENTAL PROCEDURES
| Cancer specimens and cell lines
Snap-frozen colon tissues were divided visually into tumor (T) and normal (N) regions that were then confirmed histologically. The study was approved by the ethical review board of Osaka Police Hospital (approved number 79), and informed consent was obtained from all subjects. Human colon cancer cell lines (HT-29, HCT116, HCT15, SW480, and SW620), FHC (normal human colon cells), and HaCaT (human epithelial cells) were obtained from the American Type Culture Collection (ATCC). HMECs (human mammary epithelial cells), HMLEs (HMECs expressing LT and hTERT), and HMLERs (HMLEs expressing H-rasV12) were a kind gift from Dr RA Weinberg (Elenbaas et al., 2001 ). HT29 and HCT116 cells were cultured in McCoy's 5A medium, and SW480 and SW620 cells were cultured in Leibovitz's L-15 medium. MEFs and HaCaT cells were cultured in Dulbecco's modified Eagle's medium (DMEM). Media were supplemented with 10% fetal bovine serum (FBS). FHC cells were cultured in DMEM/Ham's F-12 (1:1) with 10% FBS, 5 μg/ml insulin, 5 mg/ml transferrin, and 100 ng/ ml hydrocortisone. HMECs, HMLEs, and HMLERs were cultured according to the method described by Elenbaas et al. (2001). 4.2 | Pre-miR-137 and anti-miR-137 transfection miR-137 precursor (PM10513) and antisense miR-137 (AM10513) were purchased from Thermo Fisher Scientific. The day before transfection, 2.5 × 10 5 cells were seeded onto 6-well plates. 5 nM of precursor, 10 nM of inhibitor, and negative control were transfected using Lipofectamine RNAiMAX in 16 μl per 6-well plate, according to the manufacturer's instructions (Thermo Fisher Scientific). Using this approach, 90% of cells were transfected as judged by FAMlabeled controls (AM17121).
| Soft agar colony formation assay
Soft agar colony formation assay was performed as described (Oneyama et al., 2008b) . Single-cell suspensions of 4 × 10
| Tumorigenesis assays
Immunodeficient mice (BALB/c AJc1-nu/nu, Japan CLEA, Inc.) were injected subcutaneously (s.c.) with 1 × 10 6 cells suspended in 200 μl of serum-free McCoy'5A in the flank. Tumors were monitored every 2 or 3 days, and tumor volumes were estimated using the following formula: 0.5 × L × W 2 .
At least three mice were used in each experiment. The mice were handled in strict adherence with local governmental and institutional animal care regulations. All animal experiments were conducted in accordance with the protocols approved by the Animal Research Committee of Research Institute for Microbial Diseases in Osaka University.
| Immunochemical analysis
Cells were lysed in n-octyl-β-D-glucoside (ODG) buffer, and immunoblotting were performed as described previously (Oneyama et al., 2008b) . The following antibodies were used (sources indicated in parentheses): anti-phosphotyrosine (4G10, Millipore), anti-Src (Ab-1, Calbiochem), anti-Src pY418 (Invitrogen), anti-ERK1/2 (Cell Signaling), anti-ERK1/2 pT202/Y204 (Cell Signaling), anti-AKT pS473 (Cell Signaling), anti-AKT (Cell Signaling), anti-panAKT (Cell Signaling), anti-paxillin (BD Biosciences), anti-vinculin (Sigma), anti-K-ras (Cell Signaling), anti-GAPDH (Santa Cruz), and Alexa Fluor 594-conjugated goat anti-mouse IgG (Molecular Probes). The chemicals used were Alexa Fluor 488-phalloidin (Molecular Probes) and dasatinib (Sigma). Immunocytochemistry was performed as described previously (Oneyama et al., 2008a) . The specimens were examined by confocal laser scanning microscopy (FV-1000, Olympus).
| Luciferase assay
Two sets of complementary oligonucleotides from the 3′UTR of the human c-Src genes that contained the miR-137 putative binding site were designed and synthesized as follows: Wild-type and mutant oligonucleotides were annealed and subcloned into the region downstream of the firefly luciferase gene stop codon into the pMIR report control vector (Ambion). These products are referred to
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as pMIR-Src-wt (Src wild-type 3′ UTR) and pMIR-Src-mt (Src mutant 3′ UTR). HCT116 cells were cotransfected with 1 μg of pMIR-Src/-AKT2 and 1 μg of Renilla luciferase expression construct (pRL-TK, Promega) using Lipofectamine 2000 (Thermo Fisher Scientific). Cells were harvested 24 hr post-transfection and analyzed using the Dual Luciferase Assay (Promega) according to the manufacturer's instructions. Three independent experiments were performed in triplicate. The primers used were as follows:
Src-wt-F: 5′ AGCTTCACCATGGCCCCCTCATCATAGCA ATAACATTCCCACTGCCAGGGGTTA 3′ Src-wt-R: 5′ CTAGTAACCCCTGGCAGTGGGAATGTTA TTGCTATGATGAGGGGGCCATGGTGA 3′ Src-mt-F: 5′ AGCTTCACCATGGCCCCCTCATCATGCGG CGGCATTCCCACTGCCAGGGGTTA 3′ Src-mt-R: 5′ CTAGTAACCCCTGGCAGTGGGAATGCCG CCGCATGATGAGGGGGCCATGGTGA 3′ AKT2-wt-F: 5′ AGCTTCTTCATATTTGTACGGTACAAG CAATAAAGACACTCATTTCAGACCAGA 3′ AKT2-wt-R: 5′ CTAGTCTGGTCTGAAATGAGTGTCTTT ATTGCTTGTACCGTACAAATATGAAGA 3′ AKT2-mt-F: 5′ AGCTTCTTCATATTTGTACGGTACAG CGGCGGAGACACTCATTTCAGACCAGA 3′ AKT2-mt-F: 5′ CTAGTCTGGTCTGAAATGAGTGTCTCC GCCGCTGTACCGTACAAATATGAAGA 3′
| Retroviral gene transfer
All of the gene transfer experiments were carried out using the pCX4 series of retroviral vectors (Akagi, Sasai, & Hanafusa, 2003) . Retroviral vectors carrying wild-type chicken c-Src was kindly provided by Dr Tsuyoshi Akagi (Osaka Bioscience Institute, Osaka). The constructs of H-ras V12 and SV40 large-T antigens were kindly provided by Dr Tsuyoshi Akagi. The paxillin construct was kindly provided by Dr Hisataka Sabe (Hokkaido University). Mouse AKT2 was subcloned into pCX4bsr. Production of retroviral vectors and infection with retroviral vectors was performed according to the method described by Akagi et al. (Akagi et al., 2003) .
| Knockdown of c-Src by shRNA
Lentiviral vectors, both empty and carrying human c-Src (ID: NM_198291.1-1579s1c1) were purchased from Sigma. The production of lentiviruses and the infection of cells were performed according to the manufacturer's instructions.
| Real-time PCR analysis of miRNAs
Total RNA was prepared using Sepasol (Nacalai Tesque).
Real-time PCR analysis of miRNAs was performed as described (Oneyama et al., 2011) . Expression of mature miRNA was assayed using TaqMan MicroRNA assays (Thermo Fisher Scientific). miRNA expression was calculated relative to the expression of snoRNA (P/N: 4380914, for mouse) or RNU48 (P/N: 4373383, for human) (Thermo Fisher Scientific). MicroRNA-specific primers for miR-137 (TM001129), miR-27b (TM000409), miR-99a (TM000435), miR-503 (TM001048), and miR-542-3p (TM1284) were obtained from Thermo Fisher Scientific. Experiments were carried out in triplicate for each data point. RT was performed using 10 ng of separated RNA, and real-time PCR was performed according to the manufacturer's protocols on the Applied Biosystems 7900HT PCR Detection System (Applied Biosystems).
| Invasion assay
Invasion assays were conducted using a BioCoat Matrigel Invasion Chamber (BD Biosciences) as described (Oneyama et al., 2012) . A cell suspension (5 × 10 4 cells) in serumfree medium was added to the inserts, and each insert was placed in the lower chamber, which contained NIH3T3 cellconditioned medium. After 48 hr of incubation, invasiveness was evaluated by staining the cells that migrated through the extracellular matrix layer. Numbers of invading cells were counted for five microscopic fields per well at a magnification of 100×, and the extent of invasion was expressed as the average number of cells per mm 2 .
| Cell adhesion assay
Cells were starved overnight in serum-free medium and harvested by limited trypsin-EDTA treatment (0.25% trypsin/0.02% EDTA in PBS). Cells were collected by centrifugation, resuspended in serum-free medium, and held in suspension at 37°C for 3 hr. Cells were replated on dishes coated with 5 μg/ml fibronectin or 50 μg/ml collagen I and incubated for 90 min at 37°C. After removing the medium, the attached cells were observed under a microscope, and micrographs were used to count the number of attached cells.
| Statistical analysis
All summary data were reported as means ± SD calculated for each group and compared using the Student's t test using Excel software (Microsoft). Test results were reported as two-tailed p-values, where p < 0.05 was considered statistically significant.
